CD19
免疫学
血小板
免疫性血小板减少症
自身抗体
医学
免疫系统
调节性B细胞
B细胞
单核细胞
自身免疫
内科学
白细胞介素10
抗体
作者
Xiaojuan Li,Hui Zhong,Weili Bao,Nayla Boulad,Evangelista E Jessie,Muhammad Anis Haider,James Bruce Bussel,Karina Yazdanbakhsh
出处
期刊:Blood
[Elsevier BV]
日期:2012-08-03
卷期号:120 (16): 3318-3325
被引量:194
标识
DOI:10.1182/blood-2012-05-432575
摘要
B lymphocytes producing antiplatelet autoantibodies play a major role in autoimmune thrombocytopenia (ITP). However, certain B cells, including the human CD19(+)CD24(hi)CD38(hi) subpopulation, possess regulatory functions mediated partly by IL-10. In a cohort of chronic ITP patients with low platelet counts who consisted of patients off treatment, we found a lower frequency of CD19(+)CD24(hi)CD38(hi) in the peripheral compartment of nonsplenectomized patients (P = .03). IL-10 expression after activation was decreased in all ITP circulating CD19(+) subpopulations (P < .03), and inhibition of monocyte TNF-α expression by activated B cells was reduced in patients with platelet numbers of < 50 × 10(9) cells/L (P = .001), indicating that regulatory B cells of patients with ITP are functionally impaired in their ability to dampen monocyte activation. Interestingly, in nonsplenectomized patients whose platelet counts were elevated after treatment with thrombopoietic agents, the frequency of CD19(+)CD24(hi)CD38(hi) B cells was increased compared with those before treatment (P = .02). Altogether, these data indicate a compromised regulatory B-cell compartment as an additional defect in immune regulation in patients with chronic ITP that may be restored in responders to thrombopoietic treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI